Contrasting Fractyl Health (GUTS) & Its Peers

Fractyl Health (NASDAQ:GUTSGet Free Report) is one of 236 public companies in the “Surgical & medical instruments” industry, but how does it contrast to its rivals? We will compare Fractyl Health to related businesses based on the strength of its valuation, dividends, risk, analyst recommendations, institutional ownership, earnings and profitability.

Analyst Recommendations

This is a summary of recent ratings and target prices for Fractyl Health and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fractyl Health 0 0 3 0 3.00
Fractyl Health Competitors 1914 4910 9149 268 2.48

Fractyl Health currently has a consensus price target of $22.00, suggesting a potential upside of 913.82%. As a group, “Surgical & medical instruments” companies have a potential upside of 15.99%. Given Fractyl Health’s stronger consensus rating and higher possible upside, analysts plainly believe Fractyl Health is more favorable than its rivals.

Earnings and Valuation

This table compares Fractyl Health and its rivals top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Fractyl Health $97,000.00 -$77.09 million -0.18
Fractyl Health Competitors $1.05 billion $10.63 million -6.68

Fractyl Health’s rivals have higher revenue and earnings than Fractyl Health. Fractyl Health is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Institutional & Insider Ownership

47.9% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 15.5% of shares of all “Surgical & medical instruments” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Fractyl Health and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Fractyl Health -64,849.48% N/A -57.21%
Fractyl Health Competitors -574.62% -156.70% -27.31%

Summary

Fractyl Health rivals beat Fractyl Health on 7 of the 12 factors compared.

Fractyl Health Company Profile

(Get Free Report)

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.

Receive News & Ratings for Fractyl Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fractyl Health and related companies with MarketBeat.com's FREE daily email newsletter.